Biophenotypes of breast carcinoma in situ defined by image analysis of biological parameters

Pathology Research and Practice

Volumn 192, Issue 2, 1996, Pages 117-123

  Albonico, G ^a   Querzoli, P ^a   Ferretti, S ^a   Magri, E ^a   Nenci, I ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

Biophenotypes; Image analysis; In situ breast cancer

Indexed keywords

BIOLOGICAL MARKER; ESTROGEN; ESTROGEN RECEPTOR; PROGESTERONE; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER CLASSIFICATION; CARCINOMA IN SITU; CELL PROLIFERATION; CLINICAL ARTICLE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; ONCOGENE C ERB;

EID: 0029864237     PISSN: 03440338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0344-0338(96)80205-6     Document Type: Article

References (32)

1. Aldenderfer MS, Blashfield RK (1984) Cluster Analysis. Sage University Paper series on Quantitative Application in the Social Sciences, series no. 07-044: pp 43-45. Sage Pubns, Beverly Hills-London
2. Anderson TJ, Alexander F, Chietty U, Kirkpatrick A, Roberts MM, Lamb J, Lutz W, Forrest APM, Muir B, Huggins A (1986) Comparative pathology of prevalent and incident cancers detected by breast screening. Lancet i: 519-522
3. Barnes R, Masood S (1990) Potential value of hormone receptor assay in carcinoma in situ of the breast. Am J Clin Pathol 94: 533-540
4. Bartkova J, Barnes DM, Millis RR, Gullick WJ (1990) Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ. Hum Pathol 21: 1164-1167
5. Bobrow LG, Happerfield LC, Gregory WM, Springall RD Millis RR (1994) The Classificazion of Ductal Carcinoma in situ and its association with biological markers. Semin in Diag Pathol 11, 3: 199-207
6. Bur ME, Zimarowsky MJ, Schnitt SJ, Baker S, Lew R (1992) Estrogen receptor immunohisochemistry in carcinoma in situ of the breast. Cancer 69: 1174-1181
7. Davidoff AM, Kerns BJM, Iglehart JD, Marks JR (1991) Maintenance of the p53 alteration throughout breast cancer progression. Cancer Res 51: 2605-2610
8. Eusebi V, Feudale E, Foschini MP, Micheli A, Conti A, Riva C, Di Palma S, Rilke F (1994) Long-Term follow-up of in situ carcinoma of the breast. Sem in Diag Pathol 11, 3: 223-235
9. Fechner RE (1993) One century of mammary carcinoma in situ. What have we learned? Am J Clin Pathol 100: 654-661
10. Isola JJ, Helin HJ, Helle MJ (1990) Evaluation of cell proliferation in breast carcinoma: comparison of Ki-67 immunohistochemical study, DNA f low cytometric analysis and mitotic count. Cancer 65: 1180-1188
11. Lagios MD, Margolin FR, Westdhal PR, Rose MR (1989) Mammagrafically detected duct carcinoma in situ. Cancer 63: 618-624
12. Locker AP, Horrocks C, Gilmour AS, Ellis IO, Dowle CS, Elston CW, Blamey RW (1990) Flow cytometric and histological analysis of ductal carcinoma in situ of the breast. Br J Surg 77: 564-567
13. Locker AP, Birrell K, Bell JA, Nicholson RI, Elston CW, Blarney RW, Ellis JO (1992) Ki-67 immunoreactivity in breast carcinoma: relationship to prognostic variables and short term survival. Eur J Surg Oncol 18: 224-229
14. Lodato RF, Maguire HC, Greene MI, Weiner DB, LiVolsi V (1990) Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Modern Pathol 3: 449-454
15. Meyer JS (1986) Cell kinetics of histologic variants of in situ breast carcinoma. Breast Cancer Res Treat 7: 171-180
16. Muss BH, Thor AD, Berrey DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, Henderson C (1994) C-erb-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330: 1260
17. O'Malley FP, Vnencak-Jones CL, Dupont WD, Pari F, Manning S, Page DL (1994) P53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Lab Invest 71: 67-72
18. Page DL (1989) Cancer risk assessment in benign breast biopses. Hum Pathol 17: 871-874
19. Page DL, Dupont WD (1990) Anatomic markers of human premalignancy and risk of breast cancer. Cancer 66: 1326-1335
20. Page DL, Kidd TE, Dupont WD, Simpson JF, Rogers LW (1991) Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol 22: 1232-1239
21. Pertschuck LP, Kim DS, Nayer K, Feldman JG, Eisemberg KB, Karter AC, Tian Rong Z, Thelmo WL, Fleisher J, Greene GL (1990) Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Cancer 66: 1663-1670
22. Pollcr DN, Roberts EC, Bell JA, Elston CW, Blamey RW, Ellis IO (1993) p53 protein expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein. Hum Pathol 24: 463-468
23. Poller DN, Silverstein MJ, Gala M, Locker AP, Eltson CW, Blamey RW, Ellis IO (1994) Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification. Association between cellular proliferation and c-erbB-2 protein expression. Modern Pathol 7: 257-262
24. Querzoli P, Ferretti S, Marzola A, Tassinari D, Indelli M, Marchetti E, Fabris G, Nenci I (1992) Clinical usefulness of estrogen receptors immunocytochemistry in human breast cancer. Tumori 78: 287-290
25. Railo M, Nordling S, Von Boguslawsky K, Leivonen M, Kjllonen L, Von Smitten K (1993) Prognostic value of Ki-67 immunolabelling in primary operable breast cancer. Br J Cancer 68: 579-583
26. Ramachandra S, Machin L, Ashley S, Monaghan P, Gusterson BA (1990) Immunohistochemical distribution of c-erbB-2 in in situ breast carcinoma. A detailed morphological analysis. J Pathol 161: 7-14
27. Schnitt SJ, Silen W, Sadowsky NL, Connolly JL, Harris JR (1988) Ductal carcinoma in situ (intraductal carcinoma) of the breast. N Engl J Med 318: 898-903
28. Schonborn I, Zschiesche W, Spitzer E, Minguillon C, Mohner M, Ebeling K, Grosse R (1994) C-erb-2 overexpression in primary breast cancer: indipendent prognostic factor in patients at high risk. Breast Canc Resear and Treat 29: 287
29. Van Dongen JA, Holland R, Peterse JL, Fentiman IS, Lagios MD, Millis RR, Recht A (1992) Ductal carcinoma in situ of the breast; second EORTC consensus meeting. Eur J Cancer 28: 626-629
30. Wilbur DC, Barrows GH (1993) Estrogen and Progesterone receptor and c-erbB-2 oncoprotein analysis in pure in situ breast carcinoma: an immunohistochemical study. Modern Pathol 6: 114-120
31. Zafrani B, Leroyer A, Fourquet A, Laurent M, Trophilme D, Validire P, Sastre-Garau X (1994) Mammographically-detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: correlation with Estrogen and Progesteron receptors, p53 and c-erbB-2 proteins, and proliferative activity. Sem in Diag Pathol 11,3: 208-214
32. Zhang QX, Borg A, Fuqua SAW (1993) An Exon 5 deletion variant of the Estrogen Receptor frequently coexpressed with Wild-Type Estrogen Receptor in human breast cancer. Cancer Res 53: 5882-5889